cabozantinib

Cabozantinib Fails In the Phase III COMET-1 Trial

The pharmaceutical company Exelixis has announced that their experimental treatment, cabozantinib has failed the Phase III clinical trial for men with metastatic castration-resistant prostate cancer (mCRPC). In the trial the experimental treatment cabozantinib was compared to the drug prednisone. In the trial known as COMET-1, Cabozantinib, a tyrosine kinase inhibitor, did not meet its primary [...]

By Malecare|2017-10-19T10:48:04-04:00September 2nd, 2014|Advanced Prostate Cancer, cabozantinib, Clinical Trials, Clinical Trials, Uncategorized|0 Comments

On the Horizon – Targeting Bones in the Treatment of Advanced Prostate Cancer

Osteoblasts and osteoclasts are the process that the body uses to breakdown old bone and then to rebuild it with new bone. c-Met is a tyrosine kinase expressed by osteoblasts and osteoclasts, and overexpressed by prostate cancer cells. This over expression leads to the eventual development of bone metastases. The experimental treatment known as Cabozantinib [...]

By Malecare|2017-10-19T10:49:44-04:00June 21st, 2013|Advanced Prostate Cancer, Bone Metastases, cabozantinib, Clinical Trials, Clinical Trials,